Esperion Therapeutics Inc | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (47)

Latest Posts

About This Stock More About This Stock
"CLEAR" Progress At Esperion
Article By: MoneyShow.com
Saturday, September 16, 2023 2:19 PM EST
Esperion Therapeutics, Inc. continues to showcase their positive CLEAR data, with two oral presentations at the European Society of Cardiology 2023 Congress. Here is a closer look at some highlights.
In this article: ESPR
Read
Top Picks For 2023: Esperion
Article By: MoneyShow.com
Monday, January 2, 2023 3:59 PM EST
Esperion is a de-risked biotech company in the cardiovascular sector with its lead drug, bempedoic acid, already FDA approved to reduce LDL cholesterol. Let's take a closer look at why it's a top pick for 2023.
In this article: ESPR
Read
Monday Markets Unhinged
Article By: Vivian Lewis
Monday, May 3, 2021 4:54 PM EST
Today's stock market is somewhat unhinged because so many foreign markets are shut for a bank holiday: Britain, China, Thailand, Japan.
In this article: CCJ, KL, AZRE, NIO, ESPR, TBPH, ZYME, AQN, AY, BHC, TAK, TEVA, OCGN
Read
Esperion - Raising Prospects In Lowering Cholesterol
Article By: MoneyShow.com
Sunday, July 12, 2020 2:04 PM EST
Esperion Therapeutics just announced a pooled efficacy analysis from the four Phase III clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine.
In this article: ESPR
Read
JMP Reiterates $191 Price Target On Esperion After Japan Partnership
Article By: The Fly
Monday, April 20, 2020 1:16 PM EST
JMP Securities analyst Jason Butler reiterates an "Outperform" rating on Esperion Therapeutics, with a $191 price target after the company announced a Japanese partnership with Otsuka, for its bempedoic acid franchise.
In this article: ESPR, OTSKY
Read

Latest Tweets for $ESPR

No tweets yet!

PARTNER HEADLINES